



## Journal of University Studies for inclusive Research

Vol.3 , Issue 2 (2022 ), 2558- 2569

USRIJ Pvt. Ltd.,

### Effects of camel thorn extract on patients suffering from Hepatitis B Virus: a preliminary human study

#### Authors

Huda M. Gargoum\* هدى محمد قرقوم

Department of Pharmacology. Benghazi University. Libya

Abdel-Naser Elzouki عبدالناصر الزوكي

Hamad Medical Corporation Doha. Qatar

Awad G Abellatif عوض جمعة عبداللطيف

Department of Pharmacology. Tobruk University. Libya

Fathi M. Sherif فتحي الشريف

Department of Pharmacology, University of Tripoli, Libya

#### Address of the corresponding author \*

Name: Huda M Gargoum

Email: drhudi@yahoo.com

Tel: +218922314572

#### Abstract

Hepatitis B virus infection is a major challenge health problem worldwide. Camel thorn is used in Libyan folk medicine for hepatitis. The aim of this study is to investigate the effect of camel thorn on hepatitis B virus. After pharmacological and toxicological screening of camel thorn on experimental animals in our laboratories. By using open labeled study, 15 patients were randomly chosen with their agreement.

The patient were given a very low safe dose of camel thorn powder (2.6 gm soaked in boiling water for 10 min), TID for six months. The viral load was measured before treatment, three and six months after the beginning of experiment by polymerase chain reaction (PCR). The level of transaminases, bilirubin, creatinine, blood glucose, lipid profile, thyroid function, prothrombin were assessed before and after three months of beginning of experiment. Our data showed no significant changes in creatinine, blood urea, glucose level, bilirubin, alkaline phosphatase, lipid profile, prothrombin and thyroid function. The level of viral load before and three and six months after the beginning of our study were  $1689 \pm 289$ ,  $558 \pm 160$  and  $271 \pm 26$  IU/ml, respectively. From this study, we may conclude that the camel thorn is safe and showed activity against viral hepatitis B. Further investigations are needed by increasing the number of patients and using higher doses of plant extract to explore its mechanism of action.

عدوى فيروس التهاب الكبد B هي مشكلة صحية رئيسية في جميع أنحاء العالم. يستخدم شوكة الجمل في الطب الشعبي الليبي لالتهاب الكبد. الهدف من هذه الدراسة هو معرفة تأثير شوكة الجمل على فيروس التهاب الكبد B. بعد الفحص الدوائي والسموم لشوكة الجمل على حيوانات التجارب في مختبراتنا. باستخدام دراسة مفتوحة المسمى ، تم اختيار 15 مريضاً بشكل عشوائي بموافقتهم. أخذ المرضى جرعة منخفضة جداً وأمنة من مسحوق شوكة الجمل (2.6 جم غارقة في الماء المغلي لمدة 10 دقائق) لمدة ستة أشهر. تم قياس الحمل الفيروسي قبل العلاج ، و بعد ثلاثة و ستة أشهر من بداية التجربة بواسطة تفاعل البلمرة المتسلسل (PCR) تم تقييم مستوى الترانساميناز ، والبيلبيروبين ، والكرياتينين ، وجلوكوز الدم ، ومستوى الدهون ، ووظيفة الغدة الدرقية ، والبروثرومبين قبل وبعد ثلاثة أشهر من بداية التجربة. أظهرت بياناتنا عدم وجود تغيرات كبيرة في الكرياتينين ، واليوريا في الدم ، ومستوى الجلوكوز ، والبيلبيروبين ، والفوسفاتيز القلوي ، وملف الدهون ، والبروثرومبين ، ووظيفة الغدة الدرقية. كان مستوى الحمل الفيروسي قبل وبعد ثلاثة و ستة أشهر من بداية دراستنا  $1689 \pm 289$  ،  $558 \pm 160$  و  $271 \pm 26$  وحدة دولية / مل ، على التوالي. من هذه الدراسة ، قد نستنتج أن شوكة الجمل آمنة وأظهرت نشاطاً ضد التهاب الكبد الفيروسي B. هناك حاجة إلى مزيد من التحقيقات عن طريق زيادة عدد المرضى واستخدام جرعات أعلى من مستخلصات النبات لاستكشاف آلية عملها.

**Keywords:** Camel thorn, Transaminase, Alkaline phosphatase, Creatinine.

### Introduction

Viral hepatitis is a public health problem worldwide as well as a therapeutic challenge. Many recent used drugs may have a high toxicity. Additionally, the development of resistant mutants during the period of the treatments is another issue

with these medicines. Although the interferon (PEG-IFN) and nucleotide analog therapy are currently considered as the standard therapy for treatment of chronic hepatitis B, they are not totally effective and have several side effects (Bruix, Fonseca, & Reig, 2019; Sonneveld & Janssen, 2010). Because the reverse transcriptase of HBV lacks proof-reading function, the virus has rapid mutagenesis. Thus the virus may develop a resistance to antiviral drugs rapidly (Locarnini & Warner, 2007; Mauss & Wedemeyer, 2008). Therefore, the replacement of these drugs with medicinal plants that have lower toxicity can be useful (Govind & Pandey, 2011; Thomas, Leoutsakas, Zabransky, & Kumar, 2011).

Alhagi maurorum (Camel thorn) is a very common woody perennial shrub, rich in phenolic and flavonoid compounds (Al-Jaber, Awaad, & Moses, 2011). Camel thorn is used traditionally as a remedy for rheumatic pains, bilharziasis, liver disorders, urinary tract infection and for various types of gastrointestinal discomfort with both peripheral and central anti-nociceptive activity (Atta & El-Sooud, 2004). It has been also reported that the camel thorn shows Antioxidants, anti-diarrheal and anti-ulcerogenic activities (Awaad, Maitland, & Soliman, 2006). Based on previous studies that showed the hepatoprotective activity of this herb (Abdellatif et al., 2014; Huda, S, et al., 2013), our aim in this study is to investigate the effect of camel thorn on the load of hepatitis B virus.

## **Material and methods**

### **Preliminary human studies:**

The significant relative safety of camel thorn extract (CTE) ( $LD_{50} = 5.4$  g/kg) in mice and its significant hepato-protective effect of our previous experimental studies on animals stimulated the use of small doses of camel thorn powder (CTP) as hepato-protective agent (Huda, El-Naser, et al., 2013). The dose selected was 1.5-2 g three times a day (TID) for 6 months. This dose is extremely small compared with the  $LD_{50}$  in mice.

By open labeled study 15 patients with Hepatitis B virus but not with Hepatitis C virus were randomly chosen, with their agreements and consent forms were signed. An ethical approval was also obtained from the University Research Ethics Committee.

The patients were of either sexes and of different ages (20 to 50 yrs.). They had no liver cirrhosis or co-morbid diseases. They were not alcoholics.

All patients underwent basic investigations, including checking their body weight and blood pressure before and after CTP use. The patients used the herb orally in a dose 4.5 gm divided for 6 months.

The investigations included polymerase chain reaction test (PCR), liver function test (LFT) (includes: bilirubin, alanine transaminase (ALT), aspartate aminotransferase (AST), Alkaline, and Albumin); renal function test (RFT) (includes: Urea (Ur), creatinine (Cr)); thyroid function tests (TFT) (includes: tri-iodothyronine (T3), Tetra-iodothyronine or thyroxine (T4), thyroid stimulating hormone (TSH)); blood glucose levels; total lipid profile (including total cholesterol, triglyceride (TG), high density lipoprotein (HDL), low density lipoprotein (LDL)); complete blood count (CBC); prothrombin time (PT) and international normalized ratio (INR) were measured before and three months after receiving the CTP. PCR test was also repeated at the end of examination (after 6 months).

Thyroid function was determined in Immunoassay analyzer, Elecsys 2010 and Cobas, Roche, Austria. By use of Electrochemiluminescence immunoassay (ECLIA). Complete blood count was determined by a coulter counter, a hematology analyzer, Sysmex KX-21N, Roche, Austria. And prothrombin time determined by coagulation analyzer, Catron. All other biochemical parameters were determined using COBAS Integra 400 plus, biochemical autoanalyzer, Roche, Austria. Polymerase chain reaction for hepatitis B fragments was carried in Cobas Amplicor Analyzer, Roche, Austria, by use of Cobas Amplicor HBV Monitor Test, for HBV.

## Results

### **The potential role of CTP as an alternative treatment of the hepatitis:**

Figure (1) shows the change in the mean of the level of viremia before and after use of CTP in patients infected with HBV. The data in the table (1) revealed that there was a significant reduction ( $P = 0.02$ ,  $P = 0.01$ ) of PCR 3 and 6 months respectively, in patients with HBV infection treated with CTP.

As presented in the figure (2A), there was no significant change in the bilirubin ( $P=0.2$ ), AST ( $P=0.4$ ), ALT ( $P=0.1$ ), ALK ( $P=0.06$ ) and albumin ( $P=0.3$ ) levels in post CTP treated patients with HBV infection as compared with pre CTP patients. As compared with pre CTP treated HBV patients, the P values of blood urea ( $P=0.6$ ), creatinine levels ( $P=0.08$ ), were insignificant in HBV patients in HBV treated with CTP for three months figure (2B).

As shown in the figure (2C), in both situations when HBV infected patients treated or not with CTP, there was no significant change in the lipid profiles levels. The P value of cholesterol, TG, HDL, LDL were 0.64, 0.88, 0.9, 0.59 respectively. Although the blood level of T4 decreased in pre CTP treated patients from  $94.78 \pm 4.43$  to  $78.77 \pm 15.88$  in post CTE treated patients and the blood level of TSH elevated in pre CTP treated patients from  $2.55 \pm 0.64$  to  $3.56 \pm 0.92$  in post CTP treated patients, comparatively, there were no significant changes in the P values ( $P=0.39$ ,  $P=0.16$ ) of these level in pre and post CTE treated patients. The change in T3 blood level was also insignificant (Figure 2 D).

The blood glucose concentration ranged in normal level between 80 and 95 mg % in all pre and post CTP treated patients (Figure 2 E). There also was no significant difference between all parameters of the blood picture, (P values of RBC, WBC and Platelet = 0.88, 0.86, 0.66 respectively) (Figure 2F). The figure 2G reveals that prothrombin time and INR were slightly decreased in post CTP treated patients as compared to pre CTP treated patients. However, these variations were not significant ( $P=0.076$  and  $0.08$  respectively).




Figure 1: Effect of CTP on PCR of HBV infected patients.

\* =Significantly decreased as compared to pretreated patients ( $P < 0.05$ ).

\*\* =Significantly decreased as compared to pretreated patients ( $P < 0.01$ ).



	<b>Pre CTP</b>	<b>3 months. Post CTP</b>	<b>6 months. Post CTP</b>
<b>PCR U/ml</b>	1689 ± 289	557 ± 160	271 ± 26

**Table1: Effect of CTP on PCR in HBV infected patients**




Figure 2: Effect of CTP on the biochemical profile of HBV infected patients. A: Effect of CTP on Liver function. B: Effect of CTP on renal function. C: Effect of CTP on Lipid profile. D: Effect of CTP on Thyroid function. E: Effect of CTP on blood glucose. F: Effect of CTP on blood picture. G: Effect of CTP on PT, INR. All tests show no significant changes between pre and post CTP ingestion. All data are expressed as mean and SEM

## Discussion

Many herbs are used traditionally to treat viral infected patients (Solati, Heidari-Soureshjani, & Pocock, 2017; Thyagarajan, Jayaram, & Valliammai, 1990; Venkateswaran, Millman, & Blumberg, 1987) and several studies have revealed that camel thorn improves the transaminase enzymes in experimental animals (Abdellatif et al., 2014; Al-Saleem, Al-Wahaib, Abdel-Mageed, Gouda, & Sayed, 2019; Alqasoumi, Al-Rehaily, AlSheikh, & Abdel-Kader, 2008; Jalil et al., 2015; Maysa, 2016).

It has been shown that some herbs have several phytochemicals with potent antioxidant properties such as alkaloids, carotenoids, flavonoids (isoflavones, flavonones, and quercetin), terpenoids, polyphenols (ellagic acid, gallic acid and tannins), carotenoids,, polysaccharides (Ghasemi & Lorigooini, 2016; Govind, 2011). In our previous preliminary phytochemical screening of camel thorn, as well as in other studies, we had a clear evidence for the presence of phenolics, flavonoids, tannins and alkaloids in addition to carbohydrates and sterols (Ahmad et al., 2010; Huda, S, et al., 2013). Antioxidants treat various diseases by protecting cells against free radical-induced damage (Govind, 2011). Therefore, The mechanism of such hepatoprotective activity may be related to the flavonoids and other phytochemicals compounds of CTE (Al-Saleem et al., 2019).

In the current study, we found the viral load of HBV DNA is significantly reduced after receiving camel thorn powder, Indicating that this plant is effective against HBV. The present finding also suggests the camel thorn is not toxic since no marked change on the biochemical, hematological, and thyroid parameters were observed. Therefore the camel thorn may be considered as an alternative treatment option that exhibits minimal side effects for subjects suffering from viral infections.

The molecular mechanism behind the anti-HBV activity of the camel thorn has not been studied well. However, other studies showed that the anti-oxidant compounds in many medicinal plants have antiviral effects. Some studies reveal that phenolic acids showed antiviral effects. 3,4-*O*-dicaffeoylquinic acid and 3,5-*O*-dicaffeoylquinic acid isolated from *Laggera alata* significantly suppressed the HBsAg and HBeAg production (Hao et al., 2012; Kim, Kim, & Lee, 2007; Wu et al., 2012). In addition,



curcumin (a natural polyphenol) exhibited an inhibitory effect on HBV gene expression and replication in HBV-expressing cells by down-regulation of peroxisome proliferator-activated receptor- $\gamma$  co-activator 1 $\alpha$  (PGC-1 $\alpha$ ), a co-activator of HBV transcription (Rechtman et al., 2010). Phenols from *Swertia mussotii* inhibited the secretion of HBsAg and HBeAg and HBV DNA replication (Cao et al., 2015).

Oxymatrine (an alkaloids) from the plant Kushen (*Sophora japonica*) often is used to substitute the nucleoside analogues to lower the emergence of treatment-resistant HBV mutants (Chen, Mao, & Jiang, 2002). It has been also shown that the flavonoids have antiviral activity. Epigallocatechin-3-gallate (EGCG) from green tea inhibited HBV entry into immortalized human primary hepatocytes (Huang et al., 2014). EGCG effectively suppressed the HBsAg and HBeAg secretion in HepG2 2.2.15 cells and reduced the extracellular HBV DNA level. Interestingly, its effect was stronger than that of lamivudine (Pang, Zhao, Wang, Ma, & Xiao, 2014).

In conclusion, we found that the Camel Thorn significantly lowered the Hepatitis B viral load with no significant side effects. we suggest this may related to its anti-oxidant property of the plant. further studies are required to explore the mechanism of the antiviral effect of the Camel Thorn.

### Competing interests

The authors declare that they have no competing interests.

### Acknowledgments

The authors like to thanks Miss Sana M. Elmahjoob, Mr. Masaud Juma, Mr. A salam Elmogawab and Mr. Mohamed Soliman for their cooperation.

### References

- Abdellatif, A. G., M.Gargoum, H., A. A. Debani, M. , Bengleil, M., Alshalmani, S., Zuki, N. El, & Fitouri, O. El. (2014). Camel Thorn Has Hepatoprotective Activity against Carbon Tetrachloride or Acetaminophen Induced Hepatotoxicity, but Enhances the Cardiac Toxicity of Adriamycin in Rodents. *International Journal of Medical, Pharmaceutical Science and Engineering* 8(2).

- Ahmad, S., Riaz, N., Saleem, M., Jabbar, A., Nisar-, UR., & Ashraf, M. (2010). Antioxidant flavonoids from *Alhagi maurorum* *Journal of Asian Natural Products Research*, 12(2), 138–143.
- Al-Jaber, NA., Awaad, AS., & Moses, JE. (2011). Review on some antioxidant plants growing in Arab world. *Journal of Saudi Chemical Society*, 15, 293–307.
- Al-Saleem, MS. M., Al-Wahaib, LH., Abdel-Mageed, WM., Gouda, YG., & Sayed, HM. (2019). Antioxidant flavonoids from *Alhagi maurorum* with hepatoprotective effect. *Phcog Mag*, 15, 592-599.
- Alqasoumi, S. I., Al-Rehaily, A. J., AlSheikh, A. M., & Abdel-Kader, M. S. (2008). Evaluation of the hepatoprotective effect of *Ephedra foliate*, *Alhagi maurorum*, *Capsella bursa-pastoris* and *Hibiscus sabdariffa* against experimentally induced liver injury in rats. *Natural Product Sciences*, 14(2), 95–99.
- Atta, AH., & El-Sooud, K. Abo. (2004). The antinociceptive effects of some Egyptian medicinal plants. *J. Ethnopharmacol*, 95 (2-3), 235–238.
- Awaad, A.S., Maitland, D.J., & Soliman, G.A. (2006). Antiulcerogenic activity of *Alhagi maurorum*. *Pharmaceut. Biol.*, 44(4), 292–296.
- Bruix, J., Fonseca, LG. da, & Reig, M. (2019). Insights into the success and failure of systemic therapy for hepatocellular carcinoma. *Nat. Rev. Gastroenterol. Hepatol.*, 16, 617–630. doi: doi: 10.1038/s41575-019-0179-x
- Cao, TW., Geng, CA., Ma, YB., Zhang, XM., Zhou, J., Tao, YD., & Chen, JJ. (2015). Chemical constituents of *Swertia mussotii* and their anti-hepatitis B virus activity. *Fitoterapia*, 102, 15-22.
- Chen, YX., Mao, BY., & Jiang, JH. (2002). Relationship between serum load of HBV-DNA and therapeutic effect of oxymatrine in patients with chronic hepatitis B *Zhongguo Zhong Xi Yi Jie He Za Zhi*, 22, 335-336.
- Ghasemi, S., & Lorigooini, Z. (2016). A review of significant molecular mechanisms of flavonoids in prevention of prostate cancer. *Journal of Chemical and Pharmaceutical Sciences*, 9, 3388-3394.
- Govind, P. (2011). Medicinal plants againts liver diseases. *International Research Journal of Pharmacy* 2(5), 115-121.
- Govind, P., & Pandey, SP. (2011). Phytochemical and toxicity study of *Emblca officinalis* (Amla). *Int Res J Pharm*, 2(3), 270-272.
- Hao, BJ., Wu, YH., Wang, JG., SQ, SQ. Hu, Keil, DJ., Hu, HJ., . . . Zhao, Y. (2012). Hepatoprotective and antiviral properties of isochlorogenic acid A from *Laggera alata* against hepatitis B virus infection *J Ethnopharmacol* 144, 190-194.
- Huang, HC., Tao, MH., Hung, TM., Chen, JC., Lin, ZJ., & Huang, C. (2014). (-)-Epigallocatechin-3-gallate inhibits entry of hepatitis B virus into hepatocytes. *Antiviral Res*, 111, 100-111.
- Huda, MG., El-Naser, AZ. Abd, Idris, FE., S, SM. Saleh, Faraj, ES., Masaud, J., . . . Awad, GA. (2013). Investigation on the acute and subacute toxicity of *alhagi graecorum* in experimental animals. *International Journal of Applied Biology and Pharmaceutical Technology*, 4(3), 202-209.
- Huda, MG., S, SM. Saleh, Salmin, A., Hamdoon, AM., Naser, A. Abdel, Abdelkader, HD., . . . Awad, GA. (2013). Phytochemical screening and investigation of the

- effect of *Alhagi maurorum* (Camel thorn) on carbon tetrachloride, acetaminophen and adriamycin induced toxicity in experimental animals. *Journal of Scientific and Innovative Research* 2(6), 1023-1033.
- Jalil, R., Naveed, A., Muhammad, Y., Muhammad, A. KA., Mukhtiar, A., & Sabira, S. (2015). Phytochemical Screening and Hepatoprotective Effect of *Alhagi maurorum* Boiss (Leguminosae) Against Paracetamol-Induced Hepatotoxicity in Rabbits. *ropical Journal of Pharmaceutical Research*, 14(6), 1029-1034.
- Kim, KH., Kim, YH., & Lee, KR. (2007). Isolation of quinic acid derivatives and flavonoids from the aerial parts of *Lactuca indica* L. and their hepatoprotective activity in vitro. *Bioorg Med Chem Lett* 17, 6739-6743
- Locarnini, S., & Warner, N. (2007). Major causes of antiviral drug resistance and implications for treatment of hepatitis B virus mono-infection and coinfection with HIV. *Antiviral Therapy*, 12(3), 15–23.
- Mauss, S., & Wedemeyer, H. (2008). Treatment of chronic hepatitis B and the implications of viral resistance to therapy. *Expert Review of Anti-Infective Therapy*, 6(2), 191–199.
- Maysa, ME. (2016). Hepatoprotective effect of *alhagi maurorum* boiss (leguminosae) alcoholic extract against hepatotoxicity in rats *mbse journal*, 2016(44), 483-510.
- Pang, JY., Zhao, KJ., Wang, JB., Ma, ZJ., & Xiao, XH. (2014). Green tea polyphenol, epigallocatechin-3-gallate, possesses the antiviral activity necessary to fight against the hepatitis B virus replication in vitro. *J Zhejiang Univ Sci B*, 15, 533-539.
- Rechtman, MM., Har-Noy, O., Bar-Yishay, I., Fishman, S., Adamovich, Y., Shaul, Y., Shlomai, A. (2010). Curcumin inhibits hepatitis B virus via down-regulation of the metabolic coactivator PGC-1 $\alpha$  *FEBS Lett*, 584, 2485-2490.
- Solati, K., Heidari-Soureshjani, S., & Pocock, L. (2017). Effects and mechanisms of medicinal plants on stress hormone (cortisol): A systematic review. *World family medicine/middle east journal of family medicine* 15(9), 117-123.
- Sonneveld, M. J., & Janssen, H. L.A.A. (2010). Pros and Cons of Peginterferon Versus Nucleos(t)ide Analogues for Treatment of Chronic Hepatitis B. *Curr. Hepat. Rep.* , 9, 91–98. doi: doi: 10.1007/s11901-010-0041-7
- Thomas, D., Leoutsakas, D., Zabransky, T., & Kumar, M. (2011). Hepatitis C in HIV infected individuals: cure and control, right now. *Journal of the International AIDS Society* 14, 1-8.
- Thyagarajan, SP., Jayaram, S., & Valliammai, T. (1990). *Phyllanthus amarus* and hepatitis B. *Lancet* 336, 49-50.
- Venkateswaran, PS., Millman, I., & Blumberg, BS. (1987). Effects of an extract from *Phyllanthus niruri* on hepatitis B and Woodchuck hepatitis viruses: in vitro and in vivo studies *Proceedings of the National Academy of Sciences of the USA*, 84, 274-278.
- Wu, YH, Hao, BJ., Cao, HC., Xu, W., YJ, YJ. Li, & Li, LJ. (2012). Antihepatitis B virus effect and possible mechanism of action of 3,4-o-dicaffeoylquinic Acid in vitro and in vivo. *Evid Based Complement Alternat Med* doi: DOI: 10.1155/2012/356806



Journal of University Studies for inclusive Research (USRIJ)  
مجلة الدراسات الجامعية للبحوث الشاملة